Moreover, the 36-month beta value for ESPR is 1.01. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ESPR is 195.06M and currently, short sellers hold a 16.02% of that float. On December 03, 2024, ESPR’s average trading volume was 3.93M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ESPR) stock’s latest price update
Esperion Therapeutics Inc (NASDAQ: ESPR)’s stock price has increased by 10.71 compared to its previous closing price of 2.80. However, the company has seen a 23.02% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-18 that – An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –
ESPR’s Market Performance
ESPR’s stock has risen by 23.02% in the past week, with a monthly rise of 51.96% and a quarterly rise of 69.40%. The volatility ratio for the week is 9.90% while the volatility levels for the last 30 days are 8.67% for Esperion Therapeutics Inc The simple moving average for the past 20 days is 30.09% for ESPR’s stock, with a 39.70% simple moving average for the past 200 days.
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with BofA Securities repeating the rating for ESPR by listing it as a “Underperform.” The predicted price for ESPR in the upcoming period, according to BofA Securities is $2.50 based on the research report published on June 20, 2024 of the current year 2024.
ESPR Trading at 45.85% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.82% of loss for the given period.
Volatility was left at 8.67%, however, over the last 30 days, the volatility rate increased by 9.90%, as shares surge +52.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +84.52% upper at present.
During the last 5 trading sessions, ESPR rose by +23.02%, which changed the moving average for the period of 200-days by +16.54% in comparison to the 20-day moving average, which settled at $2.38. In addition, Esperion Therapeutics Inc saw 3.68% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Warren Eric, who sale 197 shares at the price of $2.17 back on Nov 19 ’24. After this action, Warren Eric now owns 162,355 shares of Esperion Therapeutics Inc, valued at $427 using the latest closing price.
Warren Eric, the Officer of Esperion Therapeutics Inc, proposed sale 197 shares at $2.17 during a trade that took place back on Nov 19 ’24, which means that Warren Eric is holding shares at $427 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.82 for the gross margin
The net margin for Esperion Therapeutics Inc stands at -0.29. The total capital return value is set at 0.11.
Based on Esperion Therapeutics Inc (ESPR), the company’s capital structure generated -2.45 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1. The debt to equity ratio resting at -0.71. The interest coverage ratio of the stock is 0.28.
Currently, EBITDA for the company is -150.11 million with net debt to EBITDA at -4.31. When we switch over and look at the enterprise to sales, we see a ratio of 2.49. The receivables turnover for the company is 4.36for trailing twelve months and the total asset turnover is 0.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.85.
Conclusion
To wrap up, the performance of Esperion Therapeutics Inc (ESPR) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
